EU ATMP Developers Missing Out By Failing To Use Advice On Offer
Executive Summary
Regulators and health technology assessment officials in the EU are disappointed that sponsors of advanced therapy medicinal products are not making good use of the joint scientific advice service, which can help converge regulatory and HTA requirements for these products.
You may also be interested in...
How To Improve Post-Approval Evidence Generation
A new scientific paper explains how companies can improve their post-licensing evidence generation plans by seeking scientific advice from EU regulators and health technology bodies at appropriate times during the drug development process.
Single Gateway For EMA-HTA Advice May Answer All Stakeholders’ Needs
The EU research-based pharmaceutical industry has welcomed the launch of a new single gateway for companies to seek parallel scientific advice from the European Medicines Agency and health technology assessment bodies on initial evidence generation and post-authorization data collection. The industry hopes the initiative will help deliver one single evidence package for regulatory and HTA purposes.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.